FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220784230> ?p ?o ?g. }

• W4220784230 endingPage "2327" @default.
• W4220784230 startingPage "2319" @default.
• W4220784230 abstract "Infliximab and golimumab are intravenously (IV) administered tumor necrosis factor inhibitors approved to treat moderate-to-severe rheumatoid arthritis (RA) with concomitant methotrexate. Owing to differences in biologic construct, patients with IV-infliximab treatment failure may benefit from switching to IV-golimumab. Utilizing the ACR's Rheumatology Informatics System for Effectiveness (RISE), a large electronic health records registry based in the USA, we assessed RA disease activity in patients switching from IV-infliximab to IV-golimumab. This retrospective, longitudinal, single-arm study included adults (≥ 18 years) with ≥ 1 RA diagnosis code between 2014 and 2018 and ≥ 1 IV-infliximab prescription within 6 months of a new IV-golimumab order (index date). Longitudinal assessments of disease activity using the Clinical Disease Activity Index (CDAI) were calculated in patients continuing IV-golimumab for 6-9- and 9-12-months post-switch. Paired t-tests evaluated significance of mean improvements during the follow-up periods. Most RA patients with disease activity assessments during the 6-month follow-up (N = 100; mean age: 65.3 years; 81% female; 74% white) demonstrated moderate-to-high disease activity (CDAI: 73% [38/52]) at enrollment. On average, patients showed significant improvement in disease activity within 6-9 months of switching; mean CDAI scores improved from 21.3 to 14.1 (p < 0.0001) and were durable through 9-12 months of treatment. Real-world patients with moderate-to-high disease activity who switched from IV-infliximab to IV-golimumab demonstrated significant and sustained improvements post-switch as measured by the CDAI. Key Points • This study used real-world data from the Rheumatology Informatics System for Effectiveness (RISE) registry to evaluate the efficacy of directly switching from intravenous (IV)-infliximab to IV-golimumab to control rheumatoid arthritis (RA) disease activity. • Most IV-infliximab patients had moderate-to-high disease activity at the time of the switch. • On average, IV-golimumab was effective in improving RA disease activity after switching from IV-infliximab as measured by the Clinical Disease Activity Index. • These data suggest that real-world RA patients with persistent symptoms despite treatment with IV-infliximab may realize improved disease control with a switch to IV-golimumab." @default.
• W4220784230 created "2022-04-03" @default.
• W4220784230 creator A5011376025 @default.
• W4220784230 creator A5037692645 @default.
• W4220784230 creator A5039063621 @default.
• W4220784230 creator A5041022383 @default.
• W4220784230 creator A5048967469 @default.
• W4220784230 creator A5059773615 @default.
• W4220784230 creator A5072083932 @default.
• W4220784230 date "2022-03-21" @default.
• W4220784230 modified "2023-09-26" @default.
• W4220784230 title "Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry" @default.
• W4220784230 cites W1176283365 @default.
• W4220784230 cites W1588610010 @default.
• W4220784230 cites W1937148812 @default.
• W4220784230 cites W1995118169 @default.
• W4220784230 cites W1999777294 @default.
• W4220784230 cites W2017883234 @default.
• W4220784230 cites W2061326496 @default.
• W4220784230 cites W2100039847 @default.
• W4220784230 cites W2110732019 @default.
• W4220784230 cites W2126525702 @default.
• W4220784230 cites W2126583816 @default.
• W4220784230 cites W2129168200 @default.
• W4220784230 cites W2140641725 @default.
• W4220784230 cites W2308038536 @default.
• W4220784230 cites W2319957449 @default.
• W4220784230 cites W2528297397 @default.
• W4220784230 cites W2563327068 @default.
• W4220784230 cites W2744603594 @default.
• W4220784230 cites W2884141624 @default.
• W4220784230 cites W2971217817 @default.
• W4220784230 cites W3082601534 @default.
• W4220784230 cites W3113341258 @default.
• W4220784230 doi "https://doi.org/10.1007/s10067-022-06116-z" @default.
• W4220784230 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35312895" @default.
• W4220784230 hasPublicationYear "2022" @default.
• W4220784230 type Work @default.
• W4220784230 citedByCount "1" @default.
• W4220784230 countsByYear W42207842302023 @default.
• W4220784230 crossrefType "journal-article" @default.
• W4220784230 hasAuthorship W4220784230A5011376025 @default.
• W4220784230 hasAuthorship W4220784230A5037692645 @default.
• W4220784230 hasAuthorship W4220784230A5039063621 @default.
• W4220784230 hasAuthorship W4220784230A5041022383 @default.
• W4220784230 hasAuthorship W4220784230A5048967469 @default.
• W4220784230 hasAuthorship W4220784230A5059773615 @default.
• W4220784230 hasAuthorship W4220784230A5072083932 @default.
• W4220784230 hasBestOaLocation W42207842301 @default.
• W4220784230 hasConcept C126322002 @default.
• W4220784230 hasConcept C1862650 @default.
• W4220784230 hasConcept C198451711 @default.
• W4220784230 hasConcept C2777138892 @default.
• W4220784230 hasConcept C2777226972 @default.
• W4220784230 hasConcept C2777575956 @default.
• W4220784230 hasConcept C2779134260 @default.
• W4220784230 hasConcept C2779384505 @default.
• W4220784230 hasConcept C2781290027 @default.
• W4220784230 hasConcept C71924100 @default.
• W4220784230 hasConceptScore W4220784230C126322002 @default.
• W4220784230 hasConceptScore W4220784230C1862650 @default.
• W4220784230 hasConceptScore W4220784230C198451711 @default.
• W4220784230 hasConceptScore W4220784230C2777138892 @default.
• W4220784230 hasConceptScore W4220784230C2777226972 @default.
• W4220784230 hasConceptScore W4220784230C2777575956 @default.
• W4220784230 hasConceptScore W4220784230C2779134260 @default.
• W4220784230 hasConceptScore W4220784230C2779384505 @default.
• W4220784230 hasConceptScore W4220784230C2781290027 @default.
• W4220784230 hasConceptScore W4220784230C71924100 @default.
• W4220784230 hasFunder F4320337415 @default.
• W4220784230 hasIssue "8" @default.
• W4220784230 hasLocation W42207842301 @default.
• W4220784230 hasLocation W42207842302 @default.
• W4220784230 hasLocation W42207842303 @default.
• W4220784230 hasLocation W42207842304 @default.
• W4220784230 hasOpenAccess W4220784230 @default.
• W4220784230 hasPrimaryLocation W42207842301 @default.
• W4220784230 hasRelatedWork W1491634525 @default.
• W4220784230 hasRelatedWork W1973542564 @default.
• W4220784230 hasRelatedWork W2013493693 @default.
• W4220784230 hasRelatedWork W2013915797 @default.
• W4220784230 hasRelatedWork W2039662997 @default.
• W4220784230 hasRelatedWork W2057389856 @default.
• W4220784230 hasRelatedWork W230393467 @default.
• W4220784230 hasRelatedWork W2560253859 @default.
• W4220784230 hasRelatedWork W2910509050 @default.
• W4220784230 hasRelatedWork W4241025361 @default.
• W4220784230 hasVolume "41" @default.
• W4220784230 isParatext "false" @default.
• W4220784230 isRetracted "false" @default.
• W4220784230 workType "article" @default.